Genentech Presents New Data on Actemra & Rituxan at ACR 2016 Save
At the upcoming 2016 ACR/ARHP Annual Meeting, Genentech will present 15 oral presentations from 17 abstracts relating to the use of tocilizumab and rituximab in a number of varied autoimmune conditions.
Maybe the most important will be the findings from the GiACTA trial wherein tocilizumab (Actemra) is studied in patients with active giant cell arteritis (GCA).
Another study called ENTRACTE is a Phase IV study in RA patients evaluating the risk of cardiovascular (CV) events with Actemra compared to etanercept.
Further data on the faSScinate study will detail the open label use of tocilizumab in systemic sclerosis.
Lastly, there will be a studies of rituximab use in RA and GPA/MPA.
Presentation title
Abstract number / presentation times (all times listed are Eastern Standard Time) | |
Tocilizumab studies | |
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (Stone J, et al.) | Oral presentation Abstract ID: 911 Sunday, November 13 11:00 a.m. – 12:30 p.m. |
Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial (Khanna D, et al.) | Oral presentation Abstract ID: 969 Sunday, November 13 2:30 – 4:00 p.m. |
Comparative Cardiovascular Safety of Tocilizumab vs. Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial (Giles JT, et al.) | Oral presentation Abstract ID: 3L Tuesday, November 15 4:30 – 6:00 p.m. |
Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors (Harrold L, et al.) | Poster presentation Abstract ID: 1596 Monday, November 14 9:00 – 11:00 a.m. |
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis (Kim SC, et al.) | Poster presentation Abstract ID: 2611 Tuesday, November 15 9:00 – 11:00 a.m. |
Methotrexate Adherence in an Online Network of Patients with Rheumatoid Arthritis (Katic B, et al.) | Poster presentation Abstract ID: 2532 Tuesday, November 15 9:00 – 11:00 a.m. |
Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA) (Strand V, et al.) | Poster presentation Abstract ID: 2515 Tuesday, November 15 9:00 – 11:00 a.m. |
Rituximab studies | |
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis (Cascino MD, et al.) | Poster presentation Abstract ID: 1930 Monday, November 14 9:00 – 11:00 a.m. |
Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the U.S. Corrona Registry (Harrold L, et al.) | Poster presentation Abstract ID: 1580 Monday, November 14 9:00 – 11:00 a.m. |
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.